摘要
目的观察分析血管内皮抑制素联合活血化瘀药对肝癌晚期患者的治疗效果.方法对2010年5月—2011年6月入院的肝癌晚期患者进行回顾性分析,筛选出符合标准且资料完整的患者72例,采取随机双盲法分为试验组和对照组两组(试验组32例,对照组40例),试验组采用血管内皮抑制素联合活血化瘀药治疗方案,对照组采用单用华蟾素治疗方案,用CRF量表详细记录各组患者的生理指标,并做好随访工作.结果试验组患者的生存时间较对照组患者平均延长,组间有极显著性差异,具有统计学意义(P<0.01),但两组患者的生化指标均未得到改善.经统计发现:独立预后因素均不能单独影响患者的生存时间.结论血管内皮抑制素联合活血化瘀药治疗方案疗效确切,安全有效,能延长肝癌晚期患者的生存时间,改善患者生存质量.
Objective To observe effects of endostatin combined with activating blood and removing stasis drugs on advanced liver cancer patients and summarize the best treatment program for it.Method The data from advanced liver cancer patients admitted from May 2010 to June 2011 were analyzed retrospectively and 72 patients with standard and complete data were screened out from them.The randomized double-blind method was used to divide them into two groups,an experiment group and a control group（32 cases in the experiment group and 40 cases in control group）.The patients in experiment group were treated with the therapeutic regime of vascular endostatin in combination with activating blood and removing stasis drugs,and those in control group with that of single cinobufacini.CRF scale was applied to record physiological indexes of patients and the follow-up work was carried out seriously.Results Compared with that in the control group,the average survival time of patients in the experiment group was prolonged and showed a significant difference between two groups（P0.01）,but the biochemical indexes of patients were not improved in two groups.The results showed that the independent prognostic factors alone can not affect the survival time of patients.Conclusion Endostatin combined with activating blood and removing stasis drug treatment have a precise therapeutic effect on advanced liver cancer,which can safely and effectively prolong the survival time of patients and improve the life quality of them.This study may provide a reference for the majority of medical workers.
出处
《北华大学学报（自然科学版）》
CAS
2012年第6期672-675,共4页
Journal of Beihua University（Natural Science）
基金
重庆市卫生局医学科研项目(2009-347)
关键词
血管内皮抑制素
活血化瘀
肝癌晚期
临床观察
endostatin
activating blood and removing stasis
liver cancer
clinical observation
